drug · protein

AFREZZA

updated 2mo ago

by $MNKD MANNKIND CORP🔗 ChEMBL

community read0 votes

Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for diabetes mellitus and type 2 diabetes mellitus and 46 investigational indications.

targets

Insulin receptor

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

AFREZZA

trade names

Actrapid, Afrezza, Exubera, Humulin br, Humulin r, Inpremzia

generic

INSULIN RECOMBINANT HUMAN

MOA

12.1 Mechanism of Action Insulin lowers blood glucose levels in adult patients with diabetes mellitus by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.

indication

1 INDICATIONS AND USAGE AFREZZA ® is indicated to improve glycemic control in adult patients with diabetes mellitus. AFREZZA ® is a rapid acting inhaled human insulin indicated to improve glycemic control in adult patients with diabetes mellitus. ( 1 ) Limitations of Use : Not recommended for the treatment of diabetic ketoacidosis (DKA) ( 1 ) Not recommended in patients who smoke or who have recently stopped smoking ( 1 ) Limitations of Use: AFREZZA is not recommended for the treatment of diabetic ketoacidosis (DKA) [see Warning and Precautions ( 5.6 )] . The safety and effectiveness of AFREZZA in patients who smoke have not been established. The use of AFREZZA is not recommended in patients who smoke or who have recently stopped smoking.

AFREZZA

targets

all catalysts(0)

News(0)

comments(0)

Report a data issue

🐶 often sniffed alongside

Trials studying AFREZZA